MOTIVATION LETTER The ATMAN 3.0 HealthTech Accelerator selects thirteen startups from roughly 173 pitches, and I am applying because my venture meets the exact criteria you publish: early-stage, research-based, and investment-ready. My venture predicts drug resistance mutations from protein sequence alone, with no crystal structure required. The proof-of-concept classifier achieves an AUROC of 0.804 plus or minus 0.025 on the Platinum benchmark across 553 mutations using protein-grouped cross-validation, and it covers 100 percent of mutations versus approximately 18 percent for structure-limited tools. Published state-of-the-art mCSM-lig scores about 0.70 on the same benchmark, so my model outperforms it by a meaningful margin. The clinical problem is resistance. Antimicrobial resistance kills 1.27 million people per year globally, and oncology drug resistance causes most cancer treatment failures. Current computational tools require protein crystal structures, which exist for fewer than one in five clinically relevant mutations. My method removes that bottleneck. It uses ESM-2 protein language model delta-embeddings combined with ECFP4 drug fingerprints, fed into a Random Forest classifier. This is a translational research solution that accelerates drug development timelines and improves patient outcomes, which aligns with ATMAN's demonstrated interest in AMR solutions as seen in the ATTOX selection. I am a pharmacist turned machine learning engineer. I hold a PCN license and I have regulatory literacy that most technical founders lack. I have built the entire pipeline as sole author, from data curation to model evaluation. The roadmap is concrete: fine-tune ESM-2 on the SKEMPI 3K mutation set to reach an AUROC of at least 0.70 on that benchmark, then run a pilot with Servier in Suresnes. The Servier conversation is already in progress, and I have named partners at Paris-Saclay I2BC and Institut Pasteur for validation. ATMAN's eight-week program and Demo Day structure fit my current stage. I need mentorship on investment readiness and access to a biopharma network more than I need a large check. The accelerator's focus on HealthTech startups with clinical relevance matches my venture's positioning in diagnostics and therapeutics. I am prepared to commit to the full program and to present a clear path to revenue at Demo Day. RESEARCH STATEMENT The venture addresses a specific failure in computational drug discovery: predicting which mutations confer drug resistance without requiring a protein crystal structure. Most resistance prediction tools, including mCSM-lig and similar structure-based methods, require a resolved 3D structure of the protein-ligand complex. This requirement excludes roughly 82 percent of clinically relevant mutations because their structures are not available. My method removes that dependency entirely. The technical approach combines two representations. First, ESM-2 protein language model delta-embeddings capture the evolutionary and biophysical context of a mutation by comparing the embedding of the wild-type sequence to the mutant sequence. Second, ECFP4 drug fingerprints encode the chemical structure of the drug in question. A Random Forest classifier learns the mapping from this combined representation to a resistance label. The model was trained and validated on the Platinum benchmark, a dataset of 553 mutations with protein-grouped cross-validation to prevent data leakage. The result is an AUROC of 0.804 with a standard deviation of 0.025. On SKEMPI 2.0, a harder generalization benchmark, the AUROC is 0.634, which reflects the distribution shift between training and evaluation sets and defines the next improvement target. The validation status is honest: this is a proof-of-concept, not a deployed product. The venture is pre-seed and not yet incorporated. What exists is a working classifier, a benchmark result that beats published state-of-the-art, and a clear technical roadmap. The next milestone is fine-tuning ESM-2 on the SKEMPI 3K mutation set, which contains roughly 3,000 mutations with binding affinity changes. The target is an AUROC of at least 0.70 on that benchmark. Reaching that threshold unlocks the Servier pilot, which is the first revenue opportunity. The commercial model is a software-as-a-service platform for biopharma R&D teams. A pharma company submits a protein sequence and a candidate drug; the platform returns a resistance risk profile across all possible single-point mutations. This informs lead optimization, preclinical candidate selection, and clinical trial design. The total addressable market is the computational drug discovery segment, which is growing as AI-native biotech companies replace traditional high-throughput screening. The named partners are real and in progress. Servier in Suresnes is the pilot target. Paris-Saclay I2BC and Institut Pasteur provide validation and domain expertise. Sanofi in Gentilly is a secondary commercial target. The support pipeline includes SEMIA and Quest for Health meetings in progress, WILCO One BioTech in October 2026, and applications submitted to IncubAlliance and AI House. EIC Accelerator and BPI i-Lab are future targets once incorporation is complete. The scientific risk is the SKEMPI generalization gap. The 0.634 AUROC on SKEMPI 2.0 is below the 0.70 target, and closing that gap requires fine-tuning on larger and more diverse mutation data. The commercial risk is the sales cycle for pharma partnerships, which typically runs 12 to 18 months. The mitigation is the Servier pilot, which shortens the first sales cycle by embedding with a named partner before the product is fully polished. ESSAY RESPONSE: CLINICAL RELEVANCE The clinical relevance of this venture is direct and measurable. Antimicrobial resistance caused 1.27 million deaths in 2019, and oncology drug resistance is the primary reason cancer treatments fail in metastatic disease. When a patient's tumor acquires a resistance mutation, the current standard of care is often a trial-and-error switch to a second-line therapy. My platform predicts which mutations will arise under a given drug pressure, allowing clinicians and drug developers to design combination therapies and next-generation inhibitors that target the escape routes before they emerge. The 100 percent mutation coverage is the key clinical advantage. Structure-based tools can only assess mutations in proteins with resolved crystal structures, which is about 18 percent of the clinically relevant space. My sequence-only approach covers every mutation in every protein. For a clinician treating a patient with a rare mutation in a poorly characterized protein, this is the difference between having a prediction and having nothing. The platform also supports regulatory submissions. Drug developers can include resistance mutation profiles in their IND and NDA packages, which regulators increasingly expect for antimicrobial and oncology programs. My PCN license and regulatory background position me to understand what evidence regulators require, and the platform is designed to generate that evidence in a standardized format. ESSAY RESPONSE: MARKET POTENTIAL AND SCALABILITY The market for computational drug resistance prediction is part of the broader AI drug discovery market, which is projected to exceed 4 billion USD by 2027. The specific segment, resistance prediction and mutation impact analysis, is underserved because most tools require structures. My platform addresses a bottleneck that every antimicrobial and oncology program faces. The scalability is inherent to the software model. Once the model is fine-tuned and validated, the marginal cost of serving a new customer is near zero. The platform runs on cloud infrastructure, and the compute requirements for inference are modest. The ESM-2 embeddings are precomputed, and the Random Forest inference is fast enough for interactive use. The revenue model is tiered. The first tier is a self-serve web portal for academic researchers and small biotechs at a monthly subscription. The second tier is an API for mid-size pharma with usage-based pricing. The third tier is an enterprise partnership with a named pharma partner, starting with the Servier pilot, which includes custom model fine-tuning on proprietary data and dedicated support. The Servier pilot is the anchor that validates the enterprise tier and provides the first reference customer. The geographic strategy is global from day one. The venture is Nigeria-first in terms of founder origin, but the customer base is global biopharma. ATMAN's international startup track is a fit because the product is not geography-bound; the cloud infrastructure and API model mean a customer in Boston, Basel, or Bangalore gets the same service. CHECKLIST - [ ] Confirm ATMAN 3.0 application deadline from the official programme website - [ ] Verify whether ATMAN 3.0 accepts international startups without an India entity - [ ] Prepare pitch deck in the ATMAN template if one is provided - [ ] Prepare a one-page executive summary of the venture - [ ] Prepare a financial projection model for the next 24 months - [ ] Prepare a technical appendix with the Platinum and SKEMPI benchmark results - [ ] Prepare a letter of support or introduction from Servier contact if available - [ ] Confirm the PCN license number and regulatory credentials for the application form - [ ] Prepare a 3-minute Demo Day pitch script - [ ] Prepare a list of named partners and their current status (Servier, Paris-Saclay, Institut Pasteur, Sanofi) - [ ] Confirm incorporation status and timeline for entity formation - [ ] Prepare a slide on the competitive landscape versus mCSM-lig and structure-based tools - [ ] Prepare a slide on the clinical relevance of AMR and oncology resistance with cited statistics EDITOR NOTES - Eligibility risk: ATMAN is India-based and may prioritize India healthcare needs; the strategy notes suggest international startups are considered, but this must be verified on the official website before investing time in the full application. - The SKEMPI 2.0 AUROC of 0.634 is below the 0.70 target; do not present the model as fully validated on generalization benchmarks. The Platinum result is strong, but the SKEMPI gap is the honest current limitation. - The Servier pilot is in progress, not signed. Do not claim a confirmed partnership. The application should say "conversation in progress" and "named partner" rather than "committed customer." - The venture is not yet incorporated. The application should state pre-seed, proof-of-concept validated, and not incorporated. Do not claim revenue, product-market fit, or deployed IP. - The applicant must insert personal details not in this profile: specific dates for the Servier conversations, the SEMIA and Quest for Health meeting status, and any India-specific healthcare connections that would strengthen the ATMAN application.